Rhumbline Advisers Actinium Pharmaceuticals, Inc. Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
A detailed history of Rhumbline Advisers transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 39,656 shares of ATNM stock, worth $76,536. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39,656
Previous 32,131
23.42%
Holding current value
$76,536
Previous $251,000
16.73%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ATNM
# of Institutions
79Shares Held
7.22MCall Options Held
96.6KPut Options Held
70.5K-
Black Rock Inc. New York, NY1.88MShares$3.62 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.48MShares$2.85 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA666KShares$1.29 Million0.0% of portfolio
-
State Street Corp Boston, MA610KShares$1.18 Million0.0% of portfolio
-
Marshall Wace, LLP London, X0256KShares$494,1300.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $48.6M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...